TY - JOUR
T1 - Targeted therapy and drug resistance in triple-negative breast cancer
T2 - the EGFR axis
AU - Lev, Sima
N1 - This work was supported by the Israel Science Foundation (ISF) grant no. 1530/17 and by the ISF-NSFC joint research program (grant no. 2526/16), by the MDACC-SINF grant and by a research grant from David E. Stone. Sima Lev is the incumbent of the Joyce and Ben B. Eisenberg Chair of Molecular Biology and Cancer Research.
PY - 2020/4/29
Y1 - 2020/4/29
N2 - Targeting of estrogen receptor is commonly used as a first-line treatment for hormone-positive breast cancer patients, and is considered as a keystone of systemic cancer therapy. Likewise, HER2-targeted therapy significantly improved the survival of HER2-positive breast cancer patients, indicating that targeted therapy is a powerful therapeutic strategy for breast cancer. However, for triple-negative breast cancer (TNBC), an aggressive breast cancer subtype, there are no clinically approved targeted therapies, and thus, an urgent need to identify potent, highly effective therapeutic targets. In this mini-review, we describe general strategies to inhibit tumor growth by targeted therapies and briefly discuss emerging resistance mechanisms. Particularly, we focus on therapeutic targets for TNBC and discuss combination therapies targeting the epidermal growth factor receptor (EGFR) and associated resistance mechanisms.
AB - Targeting of estrogen receptor is commonly used as a first-line treatment for hormone-positive breast cancer patients, and is considered as a keystone of systemic cancer therapy. Likewise, HER2-targeted therapy significantly improved the survival of HER2-positive breast cancer patients, indicating that targeted therapy is a powerful therapeutic strategy for breast cancer. However, for triple-negative breast cancer (TNBC), an aggressive breast cancer subtype, there are no clinically approved targeted therapies, and thus, an urgent need to identify potent, highly effective therapeutic targets. In this mini-review, we describe general strategies to inhibit tumor growth by targeted therapies and briefly discuss emerging resistance mechanisms. Particularly, we focus on therapeutic targets for TNBC and discuss combination therapies targeting the epidermal growth factor receptor (EGFR) and associated resistance mechanisms.
U2 - https://doi.org/10.1042/BST20191055
DO - https://doi.org/10.1042/BST20191055
M3 - مقالة مرجعية
C2 - 32311020
SN - 0300-5127
VL - 48
SP - 657
EP - 665
JO - Biochemical Society Transactions
JF - Biochemical Society Transactions
IS - 2
ER -